Matthew Sowa
Vice President of Lead Discovery C4 Therapeutics
My scientific background and skill set are diverse, including molecular biology, cell biology, proteomics, mass spectrometry, computational biology, computer programming, database management, bioinformatics, and structural biology (both X-ray crystallography and cryo-electron microscopy). Throughout my career, I have used these skills to make advances in the fields of biochemistry and cell biology, most notably in the area of protein-protein interactions and their functional roles in cellular biology. These efforts and others have lead to over 40 scientific publications in journals such as Cell, Nature, Molecular Cell, and Nature Cell Biology.
Seminars
Identifying why TPD is the best approach for a target is the first step to becoming the standard of care. In this session, you will explore key factors that determine when a degrader is the best strategy for your target and how to differentiate it from traditional inhibitors. We will cover:
- The unique advantages of degraders: When and why TPD outperforms conventional approaches
- The advantages of a TPD approach versus using inhibition only in regulating BRAF-V600 mutant MAPK pathway signaling in cancer
- Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate robust anticancer activity in pre-clinical models
